Case discusses potential treatments for refractory autoimmune pulmonary alveolar proteinosis, suggesting new therapeutic pathways.
Chemotherapeutic agents or regular doses of Rituximab may represent a potential therapeutic option for refractory cases of autoimmune pulmonary alveolar proteinosis.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: